EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Barleriside A, an aryl hydrocarbon receptor antagonist, ameliorates podocyte injury through inhibiting oxidative stress and inflammation

Xiao-Jun Li, Yan-Ni Wang, Wen-Feng Wang, Xiaoli Nie, Hua Miao, Ying-Yong Zhao

Frontiers in Pharmacology · 22.08.2024 · 15

DOI: 10.3389/fphar.2024.1386604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 22.08.2024. Verfasst von Xiao-Jun Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Increasing evidence shows that hyperactive aryl hydrocarbon receptor (AHR) signalling is involved in renal disease. However, no currently available intervention strategy is effective in halting disease progression by targeting the AHR signalling. Our previous study showed that barleriside A (BSA), a major component of Plantaginis semen , exhibits renoprotective effects.

Methods

In this study, we determined the effects of BSA on AHR expression in 5/6 nephrectomized (NX) rats. We further determined the effect of BSA on AHR, nuclear factor kappa B (NF-ƙB), and the nuclear factor erythroid 2-related factor 2 (Nrf2) signalling cascade in zymosan-activated serum (ZAS)-stimulated MPC5 cells.

Results

BSA treatment improved renal function and inhibited intrarenal nuclear AHR protein expression in NX-treated rats. BSA mitigated podocyte lesions and suppressed AHR mRNA and protein expression in ZAS-stimulated MPC5 cells. BSA inhibited inflammation by improving the NF-ƙB and Nrf2 pathways in ZAS-stimulated MPC5 cells. However, BSA did not markedly upregulate the expression of podocyte-specific proteins in the ZAS-mediated MPC5 cells treated with CH223191 or AHR siRNA compared to untreated ZAS-induced MPC5 cells. Similarly, the inhibitory effects of BSA on nuclear NF-ƙB p65, Nrf2, and AHR, as well as cytoplasmic cyclooxygenase-2, heme oxygenase-1, and AHR, were partially abolished in ZAS-induced MPC5 cells treated with CH223191 or AHRsiRNA compared with untreated ZAS-induced MPC5 cells. These results indicated that BSA attenuated the inflammatory response, partly by inhibiting AHR signalling.

Discussion

Both pharmacological and siNRA findings suggested that BSA mitigated podocyte lesions by improving the NF-ƙB and Nrf2 pathways via inhibiting AHR signalling. Therefore, BSA is a high-affinity AHR antagonist that abolishes oxidative stress and inflammation.

Schlagwörter

Stichwörter der Autor:innen

oxidative stress and inflammationNrf2Plantaginis semenaryl hydrocarbon receptorbarleriside Achronic kidney diseasenuclear factor kappa Bpodocyte injury

Autor:innen und Institutionen

  • School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.
  • School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.

Zitieren

APA

Li, X. J., Wang, Y. N., Wang, W. F., Nie, X., Miao, H., & Zhao, Y. Y. (2024). Barleriside A, an aryl hydrocarbon receptor antagonist, ameliorates podocyte injury through inhibiting oxidative stress and inflammation. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1386604

Vancouver

Li XJ, Wang YN, Wang WF, Nie X, Miao H, Zhao YY. Barleriside A, an aryl hydrocarbon receptor antagonist, ameliorates podocyte injury through inhibiting oxidative stress and inflammation. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1386604

BibTeX
@article{Li2024,
  author = {Li, Xiao-Jun and Wang, Yan-Ni and Wang, Wen-Feng and Nie, Xiaoli and Miao, Hua and Zhao, Ying-Yong},
  title = {Barleriside A, an aryl hydrocarbon receptor antagonist, ameliorates podocyte injury through inhibiting oxidative stress and inflammation},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1386604}
}
Kostenlos starten →